|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients without prior A/E, blood and tumor TMPRSS2-ERG independently predicted lower PSA-PFS (HR 3.3, 95% CI 1.4-7.9 and HR 1.8, 95% CI 1.02-3.3, respectively) to taxanes.
|
30807643 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In summary, the TMPRSS2 protease is expressed highly in primary and metastatic prostate cancers and is associated with tumour cell differentiation.
|
18338334 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the status of <i>TMPRSS2-ERG</i> fusion genes and interstitial genes in tumors from a large cohort of men treated surgically for prostate cancer, associating alterations with biochemical progression.
|
29127096 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we examined a series of adjacent G3 and Gleason pattern 4 (G4) tumors in radical prostatectomy specimens and found that all were concordant for the TMPRSS2:ERG gene fusion.
|
23204237 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It seems attractive to note that TMPRSS2:ERG fusion has a stronger effect as tumors positive for the oncogenic TMPRSS2:ERG have dysregulated oncomirs and tumor suppressor miRNA signature.
|
23558555 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, we found that the ability of TMPRSS2 to promote prostate cancer tumor growth and metastasis was associated with increased matriptase activation and enhanced degradation of extracellular matrix nidogen-1 and laminin β1 in tumor xenografts.
|
26018085 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, the TMPRSS2-ERG-negative PCa cases showed significantly lower expression of ABCB1 in comparison to NPT (p = 0.003) or the fusion-positive tumors (p = 0.002).
|
26459268 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No difference in the frequency of TMPRSS2 gene alterations was found between Gleason 6 and 7 tumors.
|
20736744 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
None of the tumors expressed a TMPRSS2-ETV1 fusion.
|
17390040 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
|
25852077 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our finding reveals a new post-transcriptional mechanism of TMPRSS2-ERG regulation by Src and growth signals via miR-30 providing a rationale for targeting ERG-positive castration-resistant tumors with Src inhibitors.
|
23728339 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prevalent gene fusions in prostate cancer involve androgen-regulated promoters (primarily TMPRSS2) and ETS transcription factors (predominantly ETS-regulated gene (ERG)], which result in tumor selective overexpression of ERG in two thirds of patients.
|
20160063 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate cancer (PCa) tumors harboring translocations of ETS family genes with the androgen responsive TMPRSS2 gene (ETS+ tumors) provide a robust biomarker for detecting PCa in approximately 70% of patients.
|
30367117 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reverse phase protein arrays verified that the overexpression of both PRDX3 and PRDX4 in tumor samples is negatively correlated with the presence of the TMPRSS2-ERG gene fusion.
|
22424448 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RNA from radical prostatectomy tumour specimens was analysed using cDNA-mediated, annealing, selection, extension and ligation (DASL) to determine mRNAs associated with TMPRSS2-ERG T1/E4 fusion and prognostic of biochemical recurrence.
|
20068566 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Separate calculations in 3854 cancers with and 4768 cancers without <i>TMPRSS2:ERG fusion</i> revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors.
|
31296150 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significantly higher expression of ERG was detected in TMPRSS2-ERG-positive tumors (P<0.0001), whereas more intense expression of SPINK1 was characteristic for the TMPRSS2-ERG-negative tumors (P=0.003).
|
22505341 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significantly, our results provide evidence that two distinct ERG protein isoforms are simultaneously expressed in TMPRSS2-ERG positive samples as evidenced by the concomitant detection of two mutually exclusive peptides in two patient tumors and in the VCaP prostate cancer cell line.
|
25266362 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup analyses revealed, that the prognostic value of CEBPA loss was entirely driven by tumors carrying both TMPRSS2:ERG fusions and PTEN deletions.
|
30430607 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TMPRSS2/ERG (T/E) fusion gene is present in half of all prostate cancer tumors.
|
23052253 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The TMPRSS2-ERG transcription factor has been shown to be present in primary prostate cancer tumors as well as CRPC tumors.
|
25754347 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TMPRSS2-ERG gene rearrangement status of patient samples was determined by transformation of the exon array and RNA seq expression data to robust z-scores followed by the application of a threshold>3 to define a positive TMPRSS2-ERG gene fusion event in a tumour sample.
|
26575822 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The complete absence of ERG-positive tumor areas in 6q15-deleted tumor foci further suggest that the functional consequences of 6q15 deletions may prevent the development of TMPRSS2:ERG fusions.
|
26684029 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement.
|
16951139 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results suggest that the up-regulation of TMPRSS2 gene and the down-regulation of KLK11 gene in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness as well as novel prognostic indicators for PCa.
|
19242826 |
2010 |